NEW YORK (GenomeWeb) – Paradigm Diagnostics today announced the first closing of what it expects to be a $7 million Series B financing to support the rapid commercial expansion of its PCDx tumor sequencing test.

The first tranche of the funding round, which raised $3.5 million, was led by Mesa Verde Venture Partners. Mesa Verde managing director Carey Ng also joined Paradigm's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.